Propranolol in the treatment of acute migraine attacks.
The efficacy of the beta-adrenoceptor antagonist propranolol in the acute treatment of patients in attacks of either classical (migraine with aura) or common migraine (migraine without aura) headache was assessed in a double-blind placebo-controlled crossover trial with fixed doses. The trial was carried out on 25 patients. The treatment period was set at eight weeks, with the provision of shortening or lengthening it if necessary with a maximum period of seventeen weeks. A minimum of three migraine attacks were treated during each treatment period. Patients were assessed according to: the mean duration and mean severity per treatment period of migraine attacks. The secondary efficacy assessment was made on the basis of the percentage of attacks requiring escape medication per treatment period. The study, based on the t-distribution statistical model with a confidence level of 95%, showed that propranolol had no significant effect in aborting acute attacks of migraine when compared with placebo.
Banerjee
M
M
Department of Neurology, Oldchurch Hospital, Essex, England, UK.
Findley
L
L
D000208:Acute Disease; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use*; D013223:Statistics as Topic; D013272:Stomach Diseases / Q000209:etiology; D013997:Time Factors
D011433:Propranolol